Are Cancer Biosimilars Similar and Significant Enough to Deserve More Attention?
JAMA Netw Open
.
2023 Oct 2;6(10):e2337355.
doi: 10.1001/jamanetworkopen.2023.37355.
Authors
Chen Mao
1
,
Mengfeng Li
2
Affiliations
1
Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
2
Southern Medical University Cancer Institute, Southern Medical University, Guangzhou, Guangdong, China.
PMID:
37824148
DOI:
10.1001/jamanetworkopen.2023.37355
No abstract available
MeSH terms
Biosimilar Pharmaceuticals* / therapeutic use
Drugs, Generic
Humans
Neoplasms* / drug therapy
Substances
Biosimilar Pharmaceuticals
Drugs, Generic